Page 6 - மைக்கேல் சேவேரினோ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AbbVie Submits Regulatory Applications for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA - Submissions supported by two Phase 3 studies in patients with active psoriatic arthritis in which SKYRIZI demonstrated improved skin and joint symptoms and physical function, with a greater proportion of patients achieving minimal disease activity versus placebo[1] - In the pivotal studies, patients treated with SKYRIZI received four maintenance doses a year, following two initiation doses[1] - Psoriatic arthritis is a systemic inflammatory disease that impacts the skin and joints, affecting approximately 30 percent of patients with psoriasis[2-5] - AbbVie remains committed to working with regulatory authorities to bring SKYRIZI to more patients living with immune-mediated diseases

Michael severinoPrnewswire abbvieEuropean medicines agencyBoehringer ingelheimDrug administrationHealth assessment questionnaire disability indexPsoriasis area severity indexPain numerical rating scalePatient global assessment disease activityLeeds enthesitis indexமைக்கேல் சேவேரினோபோஹெரிங்கர் இஂகல்‌ஹைம்தடிப்புத் தோல் அழற்சி பரப்பளவு தீவிரம் குறியீட்டுவலி எண் ரேடிஂக் அளவுநோயாளி உலகளாவிய மதிப்பீடு நோய் நடவடிக்கை